CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the launch of its MERSCOPE® Platform Grant Program, open to researchers in Europe and North America.
Vizgen will award the researcher with the most innovative and impactful proposal in cancer research with a full Vizgen® Lab Services MERFISH study generated on the MERSCOPE Platform.
The MERSCOPE Platform is the first and only fully customizable commercial solution for MERFISH technology, enabling high quality spatial imaging and analysis for a broad range of sample types including FFPE tissues commonly used in oncology research. Vizgen recently expanded the research community’s access to the platform with the introduction of the MERSCOPE PanCancer Pathways human pre-designed gene panel. Vizgen leveraged well renowned oncology databases including OncoKB™, MutSig, The Cancer Genome Atlas, and Hallmarks of Cancer to carefully curate an ideal list of 500 oncology focused genes.
The PanCancer Pathways Panel enables the spatial analysis of frequently mutated genes and other genomic abnormalities common to many different cancers. Utilizing the panel, researchers have the ability to characterize tumor behavior at cellular and subcellular levels across multiple types of cancers, including breast, lung, liver, prostate, colon, melanoma, ovarian, and brain cancer.
“At Vizgen we are constantly developing new ways to innovate and expand the reach of spatial genomics as an essential tool for academic research and the life science industry,” said Terry Lo, President and CEO of Vizgen. “We are thrilled to offer this grant program as part of our ongoing efforts to increase the accessibility of spatial genomics to the scientific research community.”
Eligible researchers are invited to apply with a description of their proposed project, including specific objective, innovation and approach. The deadline to submit a nomination is June 30, 2023 and the winner will be announced in August 2023. For more information on the grant program and to apply, visit info.vizgen.com/pancancer-grant-app.
About Vizgen
Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.
